Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 583 of 2,219.
    «« First « Previous 579  580  581  582  583  584  585  586  587  Next» Last»»
    EudraCT Number: 2009-017806-36 Sponsor Protocol Number: CRC287 Start Date*: 2010-11-03
    Sponsor Name:University of Surrey
    Full Title: Effect of Vitano® on physiological and psychological responses to psychological stress assessed under laboratory conditions and in everyday life.
    Medical condition: Psychological stress
    Disease: Version SOC Term Classification Code Term Level
    12 10037175 Stress LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004176-35 Sponsor Protocol Number: PSA-201-DMF Start Date*: 2014-02-10
    Sponsor Name:Department of Rheumatology, Skåne University Hospital
    Full Title: A randomized, double blind, placebo-controlled, proof-of-concept study of FP187 in patients with mild to moderate Psoriatic Arthritis
    Medical condition: Mild to moderate psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004223-37 Sponsor Protocol Number: CQVA149ADE04 Start Date*: 2014-03-24
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, multicenter, open-label, cross-over study to assess lung function and patient preference after a 4 week treatment each with QVA149 vs. tiotropium in patients with stable chronic obstr...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004589-14 Sponsor Protocol Number: BC1036-001 Start Date*: 2012-05-17
    Sponsor Name:Respicopea Limited
    Full Title: A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough
    Medical condition: Chronic and sub acute persistent cough
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10066656 Chronic cough LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10070801 Persistent cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004293-26 Sponsor Protocol Number: QTM/GEP0512 Start Date*: 2013-09-03
    Sponsor Name:GeiserPHARMA SL
    Full Title: Multisite, open, randomized, parallel and controlled clinical trial, to evaluate the efficacy and safety of a laxative fiber formula compared to Plantaben on objective and subjective parameters of ...
    Medical condition: Occasional constipation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019267-11 Sponsor Protocol Number: MA-PA25CF10-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Axcan Pharma Inc.
    Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, CROSS-OVER STUDY TO COMPARE THE SAFETY AND EFFICACY OF PANZYTRAT® 25 000 TO KREON® 25 000 IN THE CONTROL OF STEATORRHEA IN SUBJECTS AGED 7 YEARS AND OLDER WI...
    Medical condition: Correction of steathorrea associated with chronic exocrine pancreatic insufficiency in cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10033628 Pancreatic insufficiency PT
    13.1 10017947 - Gastrointestinal disorders 10041968 Steatorrhea LLT
    13.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003269-33 Sponsor Protocol Number: CD-RI-MEDI9929-1146 Start Date*: 2014-02-18
    Sponsor Name:MedImmune LLC(a wholly owned subsidiary of AstraZeneca PLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA )
    Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) LT (Completed) LV (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-003290-95 Sponsor Protocol Number: 8835-007 Start Date*: 2014-04-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY WITH A 78-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MEL...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-001279-19 Sponsor Protocol Number: 20120187 Start Date*: 2014-03-26
    Sponsor Name:Amgen, Inc
    Full Title: A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
    Medical condition: Post Menospausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011473-33 Sponsor Protocol Number: CRAD001AFR10 Start Date*: 2009-06-22
    Sponsor Name:Novartis Pharma S.A.S.
    Full Title: Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés...
    Medical condition: Renal Transplantation
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002388-25 Sponsor Protocol Number: 703 Start Date*: 2014-04-01
    Sponsor Name:Azienda Ospedaliera Ospedali Riuniti Marche Nord
    Full Title: Phase II study to evaluate the safety and the efficacy of rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone (R-COMP 14) as front-line therapy for patien...
    Medical condition: Active and untreated Waldenstrom Macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10054693 Von Waldenstrom macroglobulinemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002396-17 Sponsor Protocol Number: NA Start Date*: 2013-12-04
    Sponsor Name:Birmingham Community Healthcare NHS Trust
    Full Title: The effect of Pramipexole on recovery from chronic post-stroke aphasia
    Medical condition: Post-stroke aphasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002408-15 Sponsor Protocol Number: Ipi4 Start Date*: 2013-11-05
    Sponsor Name:Oslo University Hospital
    Full Title: Phase IV ipilimumab in melanoma A National, Multicenter, Interventional Study in Patients with Unresectable or Metastatic Melanoma
    Medical condition: Patients diagnosed with unresectable or metastatic melanoma, cutaneous, ocular, mucosal and unknown primary tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002418-11 Sponsor Protocol Number: RH01913 Start Date*: 2013-08-12
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A study to evaluate the effect of a 67% Sodium Bicarbonate containing toothpaste on Chlorhexidine Digluconate tooth staining
    Medical condition: Tooth discolouration (a labelled undesirable effect of Corsodyl 0.2% mouthwash)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10044032 Tooth discolouration PT
    14.1 10021881 - Infections and infestations 10018292 Gingivitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2013-002439-10 Sponsor Protocol Number: PAKA-33601-AS117013 Start Date*: 2013-10-23
    Sponsor Name:University of Warwick [...]
    1. University of Warwick
    2. University Hospitals Coventry & Warwickshire NHS Trust
    Full Title: Perioperative Analgesia for Knee Arthroplasty: A prospective randomised controlled trial
    Medical condition: Osteoarthritis of the knee is a common problem; it causes inability to walk without pain and a reduction in activity levels. Total knee replacements are performed for relief of this disabilitating ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002467-26 Sponsor Protocol Number: 480-SFA2013-001 Start Date*: 2013-08-30
    Sponsor Name:480 Biomedical, Inc.
    Full Title: The SPRINT trial: An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System v1.2 in the Treatment of de novo SFA Lesions
    Medical condition: An evaluation of the safety and performance of the STANZA DRS v1.2 system for the treatment of patients with obstructive superficial femoral artery disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006154-17 Sponsor Protocol Number: 20080537 Start Date*: 2009-07-20
    Sponsor Name:Amgen Inc
    Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastati...
    Medical condition: medical condition should be "Bone Loss in patients undergoing androgen-deprivation therapy (ADT) for non-metastatic prostate cancer"
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065687 Bone loss LLT
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) CZ (Completed) HU (Completed) PL (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-001955-11 Sponsor Protocol Number: AP105162012 Start Date*: 2013-12-26
    Sponsor Name:Psicofundación. Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicología
    Full Title: A pilot study to treat emotional disorders in Primary Care with evidence-based psychological techniques: A randomized controlled trial
    Medical condition: Emotional disorders specified as anxiety disorders (e.g., panic disorder, generalized anxiety disorder, social phobia, specific phobia), mood disorders (e.g., major depressive disorder, dysthymia),...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003050-25 Sponsor Protocol Number: 28431754DIA4003 Start Date*: 2014-01-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus
    Medical condition: Patients with type 2 diabetes mellitus (T2DM) receiving standard of care but with inadequate glycemic control and at elevated risk of cardiovascular (CV) events
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) IT (Completed) NL (Completed) ES (Completed) HU (Completed) CZ (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003058-25 Sponsor Protocol Number: 1320 Start Date*: 2013-11-05
    Sponsor Name:University Hospital Grenoble
    Full Title: PREMATURE EVALUATION OF THE ANSWER BY TEP HAS THE CHOLINE IN THE METASTATIC PROSTATE CANCER
    Medical condition: METASTATIC PROSTATE CANCER
    Disease:
    Population Age: Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 579  580  581  582  583  584  585  586  587  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 04:08:04 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA